Drug Type Immune stimulating antibody conjugate (ISAC) |
Synonyms BPT331CAPS, PD1-IL2CAPS |
Target |
Mechanism IL-2Rβγ agonists(Interleukin-2 Rβγ agonists), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Bright Peak Therapeutics AGStartup |
Active Organization Bright Peak Therapeutics AGStartup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CH | Bright Peak Therapeutics AGStartup | 04 Mar 2022 |